Over 90 Total Lots Up For Auction at One Location - WA 04/08

The latest in proton and radiotherapy technology

by Lisa Chamoff, Contributing Reporter | October 10, 2022
Rad Oncology
From the October 2022 issue of HealthCare Business News magazine


The system’s smaller size makes it possible to install in compact urban areas at a reduced cost and with a shorter installation time, according to the company.

IBA
Last September, IBA and SCK CEN, the Belgian Nuclear Research Centre, announced a strategic partnership to enable large-scale production of Actinium-225, a novel radioisotope that has potential cancer treatment applications. Research is underway for its use in treating prostate, lung, colon, breast, pancreatic, blood and kidney cancers, as well as glioblastomas.

Actinium-225 has a high cytotoxic potency within a very short range, meaning it targets cancer cells while sparing surrounding healthy tissue, according to the company. IBA and SCK CEN are currently evaluating the project’s technical and economic feasibility.

IBA continues to develop its Proteus proton therapy product line, and has been delivering 45 treatment fractions per day on its ProteusONE compact open gantry solution, said Nicolas Denef, global marketing director at IBA.

“The open gantry allows for treatment of all proton therapy indications, both simple and complex, and has shown average treatment times of under 20 minutes at several treatment sites,” Denef said. “(The) combination of oblique and CBCT imaging allows practitioners to tailor the imaging needed for the patient.”

In 2022, IBA delivered its ProteusONE and ProteusPLUS systems to facilities in the U.S., China, Taiwan and India.

Leo Cancer Care
Over a year ago, the Centre Leon Berard in France began using Leo Cancer Care’s proton therapy upright patient positioning system for preclinical research, which they plan to publish in the next six months.

“They've been assessing things like patient acceptance to being positioned upright rather than laying down, said Stephen Towe, the chief executive officer of Leo Cancer Care. “The resounding result is that — no surprise to us, but it’s great that it's been validated by them — the patients do prefer being positioned upright rather than laying down on a solid table. And they've also shown that patients can be set up two to three times faster in the upright position compared to laying down, so patient throughput is improved and overall patient experience is improved.”

The company recently secured two more partnerships in the U.S., with the McLaren Proton Therapy Center in Flint, Michigan, and UW Health, the integrated health system of the University of Wisconsin-Madison, installing the company’s upright treatment technology for proton therapy.

You Must Be Logged In To Post A Comment